Reprogrammed Lipid Metabolism-Associated Therapeutic Vulnerabilities in Prostate Cancer

Area of Science:

• Oncology
• Metabolic pathways
• Biochemistry

Background:

• Prostate cancer (PCa) is a leading cause of cancer mortality in men.
• PCa exhibits significant metabolic reprogramming, especially in lipid metabolism.
• Altered lipid metabolism is implicated in PCa development, progression, and therapeutic resistance.

Purpose of the Study:

• To review the pivotal role of lipid metabolism in PCa.
• To highlight key enzymes, transcription factors, and signaling pathways involved.
• To explore therapeutic opportunities targeting lipid metabolism in PCa.

Main Methods:

• Literature review of studies on lipid metabolism and PCa.
• Analysis of key enzymes (e.g., FASN, ACLY) and transcription factors (e.g., SREBPs, FABPs).
• Examination of androgen receptor signaling in regulating lipogenesis.

Main Results:

• Lipid metabolic pathways (synthesis, uptake, oxidation, cholesterol) are crucial for PCa.
• Androgen receptor signaling drives a lipogenic phenotype supporting tumor growth.
• Tumor microenvironment interactions with lipid metabolism promote immune evasion and metastasis.

Conclusions:

• Targeting lipid metabolism presents promising therapeutic avenues for PCa.
• Inhibiting key enzymes (FASN, SREBP1/2, HMGCR, FABPs) shows preclinical and clinical potential.
• Combinatorial strategies with conventional therapies may improve PCa outcomes.